Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Maintains "Buy" Rating from Goldman Sachs

Font: Financial Modeling Prep  • Jan 14, 2026

• Goldman Sachs reiterates a "Buy" rating for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), indicating confidence in the company's growth potential.
• The stock price of Madrigal Pharmaceuticals experienced a decrease of 3.26%, showing market volatility.
• Madrigal's presentation at the 44th Annual J.P. Morgan Healthcare Conference highlights its strategic direction and developments in the NASH space.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapies for cardiovascular and metabolic diseases. The company is known for its research in liver-related conditions, particularly non-alcoholic steatohepatitis (NASH). Madrigal competes with other pharmaceutical companies in the NASH space, striving to bring effective treatments to market.

On January 14, 2026, Goldman Sachs reiterated its "Buy" rating for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with the stock priced at approximately $493.90. This endorsement from a major financial institution suggests confidence in Madrigal's potential for growth. The stock's current price reflects a decrease of 3.26%, or $16.63, from its previous value, indicating some volatility in the market.

Madrigal Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference, a key event for healthcare companies to highlight their progress and future plans. This presentation likely provided insights into Madrigal's latest developments and strategic direction, which are crucial for investors and stakeholders. The stock's fluctuation between $493.19 and $514.36 during the day reflects the market's response to such updates.

The company's market capitalization is approximately $10.95 billion, indicating its size and value in the market. With a trading volume of 430,259 shares, there is significant interest in Madrigal's stock. Over the past year, the stock has seen a high of $615 and a low of $265, showcasing its potential for both growth and risk.